INDOLENT SYSTEMIC MASTOCYTOSIS
Clinical trials for INDOLENT SYSTEMIC MASTOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new INDOLENT SYSTEMIC MASTOCYTOSIS trials appear
Sign up with your email to follow new studies for INDOLENT SYSTEMIC MASTOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug avapritinib tracked in real life for Hard-to-Control mast cell disease
Disease control Recruiting nowThis study follows about 80 people in Germany who have indolent systemic mastocytosis (ISM) and are starting avapritinib as part of their normal care because other treatments haven't controlled their symptoms well enough. Researchers will track changes in quality of life and othe…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New hope for mastocytosis sufferers: BLU-263 trial targets stubborn symptoms
Symptom relief Recruiting nowThis study tests a new drug called elenestinib (BLU-263) for people with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. About 534 adults will receive either the drug or a placebo alongside their usual symptom-relief medications. The g…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated May 11, 2026 20:53 UTC
-
New study tracks daily life with rare mast cell disorder
Knowledge-focused Recruiting nowThis study watches 150 adults with indolent systemic mastocytosis (ISM) to see how the disease affects them over time. Researchers will collect information on symptoms, treatments, and quality of life through questionnaires and lab tests. No new treatment is given; the goal is to…
Matched conditions: INDOLENT SYSTEMIC MASTOCYTOSIS
Sponsor: Blueprint Medicines Corporation • Aim: Knowledge-focused
Last updated May 17, 2026 08:03 UTC